myostatin inhibitory core peptide

Myostatin inhibitory core peptide (also known as p29) is a 29-amino acid peptide derived from the N-terminal prodomain of the myostatin precursor protein. It acts as a dual-action inhibitor of myostatin (GDF8) and growth differentiation factor 11 (GDF11) by binding to the mature ligand in circulation and blocking its interaction with type I (ALK4, ALK5) and type II (ActRIIA, ActRIIB) membrane receptors. Developed by Kawasaki Medical School in collaboration with the University of Tokyo and PeptiDream, the peptide is being optimized using hinge crosslinking technology to enhance stability and muscle permeability. It is under preclinical evaluation for the treatment of muscular dystrophies, including Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophy type D3 (LGMD D3).